Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia.
about
Autophagy in plasma cell pathophysiologyTrial Watch: Proteasomal inhibitors for anticancer therapyProteasome inhibitors in cancer therapyThe 26S proteasome complex: an attractive target for cancer therapyDefining the role of TORC1/2 in multiple myeloma.Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis.Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedsideRevisiting the role of the immunoproteasome in the activation of the canonical NF-κB pathway.The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.Inhibitors of the immunoproteasome: current status and future directionsHigher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.Methods for 20S Immunoproteasome and 20S Constitutive Proteasome Determination Based on SPRI Biosensors.Emerging drugs for Waldenström's macroglobulinemia.Targeting the bone marrow in Waldenstrom macroglobulinemia.New proteasome inhibitors in myeloma.Proteasome inhibitors in acute leukemia.The bone marrow microenvironment in waldenstrom macroglobulinemia.Novel treatment options for Waldenström macroglobulinemiaWaldenström macroglobulinemia: from biology to treatment.Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström macroglobulinemia.Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Molecular mechanisms of acquired proteasome inhibitor resistance.Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.Molecular basis of the selectivity of the immunoproteasome catalytic subunit LMP2-specific inhibitor revealed by molecular modeling and dynamics simulations.Proteasome-associated deubiquitinases and cancer.Immunoproteasome in the blood plasma of children with acute appendicitis, and its correlation with proteasome and UCHL1 measured by SPR imaging biosensors.A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.Pluripotent Stem Cell Model of Nakajo-Nishimura Syndrome Untangles Proinflammatory Pathways Mediated by Oxidative Stress.
P2860
Q27015920-B16523F9-2CBA-45EE-AC57-0B85C50FCD13Q28082910-5EFB3341-21DC-415A-8423-497367A6454CQ34939959-7D01A452-0A43-40C1-A4F1-449508BF170EQ35624079-C60AB0C5-D46C-42A6-810F-E06D8A434E0EQ35631315-9C104690-273C-4F7D-8A99-95EC12A16DD9Q35764713-DFC9C084-DB30-4386-8416-FBEDC3782BF1Q35989980-C78A4649-F32C-481A-B42E-78A33ADC4089Q36291429-62A5C0FB-CA66-46C2-9778-23A476DD7664Q37166798-1E9CF3FD-0908-4584-B5A9-82C0A582D4EDQ37292307-E8F944D0-CA88-4DF5-97F3-E3A8B787DD36Q37377911-EF94B4FD-8B48-4158-8310-698A2F13BEDFQ37703203-FDBC00D3-15E1-4328-B0F6-785AE8867E93Q37847176-BFC93EA1-6D52-4629-8847-29B49C0E4A54Q37950586-EDCDA86C-EABF-4400-9EC1-1FCBFFF5F944Q38052079-4DBAAFEF-E539-41FC-8490-0A7DFCF6F05EQ38088003-C2C00CE4-8B4A-41AD-9942-5A651E7A1BF1Q38095959-73C07D90-BA96-434A-883F-CCF1B0D55D18Q38167433-5AE6E72C-A359-4715-89A6-F39BF12268EDQ38176969-DB3115F4-43E3-4A9C-9930-EE0BDC091D96Q38202977-A1EBD7CF-CF59-4122-B9AF-AD904D17882EQ38884712-5184EA6E-A536-496B-BD9E-BAAB063ED9BBQ39034873-04474182-0D46-46D1-BFCB-009673ECDC32Q39234159-6123D43F-84C8-4686-B8CA-DF4C0C491E87Q39278628-73B1DD47-B7D7-40F1-96F0-D610D77E42C6Q39289240-CBBEE876-4CE2-4D6A-B124-0CF8E1344BBDQ42420033-820684D4-CEAB-48DB-8372-E56E3E84E678Q47161331-4FB15F76-AF83-47C6-8C6F-6A5B4CC42A35Q47757096-6FDD628D-3AEB-4BC0-BE04-33FB14E51BA8Q48117457-4463C0DA-468E-4317-9485-5D92994AE4FBQ50251604-C27706D5-5534-48E6-8C20-FA413EFB53A9Q54957638-3C5A2E74-FEA9-4A75-8D1B-AF3AF2302BFB
P2860
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Selective inhibition of chymot ...... Waldenstrom macroglobulinemia.
@en
type
label
Selective inhibition of chymot ...... Waldenstrom macroglobulinemia.
@en
prefLabel
Selective inhibition of chymot ...... Waldenstrom macroglobulinemia.
@en
P2093
P2860
P50
P1433
P1476
Selective inhibition of chymot ...... Waldenstrom macroglobulinemia.
@en
P2093
Abdel Kareem Azab
Irene M Ghobrial
Judith Runnels
Monette Aujay
Patricia Maiso
Phong Quang
Susan Demo
P2860
P304
P356
10.1182/BLOOD-2009-09-243402
P407
P577
2010-01-28T00:00:00Z